# US 2022/0031673 A1 · Novel Compositions and Methods for Treating or Preventing Dermal Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031673 A1
- Document ID: US20220031673A1
- Status: Published application
- Kind: A1
- Application number: 17/399,763
- Filed: 2021-08-11
- Published: 2022-02-03
- Earliest claimed: 2015-09-24
- Assignees: Drexel University
- Applicants: Drexel University
- Inventors: Christian Sell; Timothy Nacarelli; Ashley Azar
- Web page: https://patentgrep.com/patent/US20220031673A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 17/00: Drugs for dermatological disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.

## Claims

### Claim 1

A method of treating or preventing an age-related dermal disorder in a mammalian subject in need thereof, the method comprising topically administering to the subject a composition comprising a therapeutically effective amount of a mTORC1 inhibitor, or a salt, solvate, enantiomer or diastereoisomer thereof, wherein the age-related dermal disorder is at least one selected form the group consisting of dermal atrophy, seborrheic or actinic keratosis, pseudoscars, lentigines, focal areas of dermal thickening, and coarse wrinkles.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mTORC1 inhibitor is at least one selected from the group consisting of BEZ235, rapamycin, everolimus, AZD8055, Temsirolimus, KU-0063794, PI-103, Torkinib, Tacrolimus, Ridaforolimus, INK-128, Voxtalisib, Torin-1, Omipalisib, OSI-027, PF-04691502, Apitolisib, GSK1059615, WYE-354, Gedatolisib, AZD-2014, Torin-2, WYE-125132, BGT226, Palomid-529, PP121, WYE-687, CH5132799, Way-600, ETP-46464, GDC-0349, XL388, and Zotarolimus, or a salt, solvate, enantiomer or diastereoisomer thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the mTORC1 inhibitor is at least one selected from the group consisting of rapamycin, Ridaforolimus, and Everolimus, or a salt, solvate, enantiomer or diastereoisomer thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the mTORC1 inhibitor is rapamycin, or a salt, solvate, enantiomer or diastereoisomer thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition comprises about 0.001-1% by weight of the mTORC1 inhibitor, or a salt, solvate, enantiomer or diastereoisomer thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein the mTORC1 inhibitor is rapamycin, or a salt, solvate, enantiomer or diastereoisomer thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition further comprises a dermatologically acceptable carrier.

### Claim 9 (depends on 8)

The method of claim 8, wherein the dermatologically acceptable carrier is at least one selected from the group consisting of a solvent, lubricant, emollient, emulsifier, moisturizer, thickening wax, softener, fragrance, preservative, and artificial color.

### Claim 10 (depends on 8)

The method of claim 8, wherein the dermatologically acceptable carrier comprises petrolatum.

### Claim 11

A method of increasing the lifespan, preserving cell organization, or preventing or minimizing senescence of a mammalian fibroblast, the method comprising contacting the fibroblast with a composition comprising an effective amount of a mTORC1 inhibitor or a salt, solvate, enantiomer or diastereoisomer thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the mTORC1 inhibitor is at least one selected from the group consisting of BEZ235, rapamycin, everolimus, AZD8055, Temsirolimus, KU-0063794, PI-103, Torkinib, Tacrolimus, Ridaforolimus, INK-128, Voxtalisib, Torin-1, Omipalisib, OSI-027, PF-04691502, Apitolisib, GSK1059615, WYE-354, Gedatolisib, AZD-2014, Torin-2, WYE-125132, BGT226, Palomid-529, PP121, WYE-687, CH5132799, Way-600, ETP-46464, GDC-0349, XL388, and Zotarolimus, or a salt, solvate, enantiomer or diastereoisomer thereof.

### Claim 13 (depends on 11)

The method of claim 11, wherein the mTORC1 inhibitor comprises rapamycin, or a salt, solvate, enantiomer or diastereoisomer thereof.

### Claim 14 (depends on 11)

The method of claim 11, wherein the fibroblast is a dermal fibroblast.

### Claim 15 (depends on 14)

The method of claim 14, wherein the dermal fibroblast is in vivo and part of a mammalian subject's skin.

### Claim 16 (depends on 11)

The method of claim 11, wherein the composition is applied topically to the skin of the subject.

### Claim 17

A kit for treating or preventing an age-related dermal disorder in a mammalian subject in need thereof, the kit comprising: a composition comprising a therapeutically effective amount of a mTORC1 inhibitor or a salt, solvate, enantiomer or diastereoisomer thereof, an applicator, and instructions for topically administering the composition to the subject, wherein the dermal disorder is at least one selected form the group consisting of dermal atrophy, pseudoscars, seborrheic or actinic keratosis, lentigines, focal areas of dermal thickening, and coarse wrinkles.

### Claim 18 (depends on 17)

The kit of claim 17, wherein the mTORC1 inhibitor is rapamycin or a salt, solvate, enantiomer or diastereoisomer thereof.
